thiopurine methyltransferase, thiomethytransferase, ARUP #92066, EPIC: LAB6343, SOFT: XTMPT
This test is used to detect those individuals with low TPMT (approximately 10% of the population) who will have excessive and potentially lethal myelosuppression when given standard doses of azothioprine or 6-MP.
Specimen Collection Criteria
Collect (preferred specimen): One Dark Green-top Lithium or Sodium Heparin tube.
Also acceptable: One Lavender-top EDTA tube.
Physician Office/Drawsite Specimen Preparation
Do not centrifuge. Refrigerate (2-8°C or 36-46°F) speicmens in original collection tube immediately after collection.
Preparation for Courier Transport
Transport: 4.0 mL whole blood, refrigerated (2-8°C or 36-46°F). (Min: 3.0 mL)
- Frozen specimens.
- Specimens not collected and processed as indicated.
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 3 hours
Refrigerated (2-8°C or 36-46°F): 6 days
Frozen (-20°C/-4°F or below): Unacceptable
Specimen Storage in Department Prior to Disposal:
Specimen retention time is determined by the policy of the reference laboratory. Contact the Sendout Laboratory with any questions.
Sent to ARUP Laboratories, Salt Lake City, UT.
Monday, Wednesday, Friday.
Results available in 4-6 days.
Enzymatic/Quantitative Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Azothioprine (Imuran) and 6-Mercaptopurine (6-MP, Perinethol) are thiopurine drugs that are used to treat neoplasms and a variety of rhematologic, dermatologic, or neurologic diseases in which the immune system is thought to play a role. Although thiopurines are very useful drugs, they are also potentially toxic. The metabolic conversion of azothioprine and 6-MP to purine neocleotides and their subsequent incorporation into DNA is important in its therapeutic efficacy but also plays a role in its toxicity. The enzyme thiopurine methyltransferase (TPMT) inactivates these thiopurines by thiol methylation. A balance is established between competing metabolic pathways such that sufficient drug is converted to the active antimetabolite for therapeutic efficacy but not so much as to lead to myelotoxicity (bone marrow suppression).
ARUP #92066, EPIC: LAB6343, SOFT: XTMPT
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.
This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills,
Grosse Pointe, Royal Oak, and Troy campuses.